Compare OCSL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | GHRS |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 947.2M |
| IPO Year | 2007 | 2021 |
| Metric | OCSL | GHRS |
|---|---|---|
| Price | $11.75 | $22.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $12.63 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 757.4K | 193.7K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.63 | $10.96 |
| 52 Week High | $14.77 | $24.66 |
| Indicator | OCSL | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 61.36 |
| Support Level | $10.88 | $12.65 |
| Resistance Level | $13.19 | $22.88 |
| Average True Range (ATR) | 0.28 | 1.49 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 11.89 | 58.59 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.